Skip to main content
. 2023 Jun 1;13(7):1391–1407. doi: 10.1007/s13555-023-00935-x

Table 3.

Summary of medications under investigation for HS treatment recently completed and active but not recruiting clinical trials with primary completion date between 1 January 2021 and 22 April 2023

Clinical trial no. Clinical trial phase Agent Target/mechanism Outcome
NCT03926169 [58] Phase 2 Risankizumab IL-23A monoclonal antibody HiSCR week 16: non-superior to placebo; 43–47% (versus 42%)
NCT04979520 [87] Phase 1 Brodalumab IL-17 inhibitor Results not posted
NCT04901195 [88] Phase 3 Bimekizumab IL-17A/F inhibitor Results not posted
NCT04430855 [89] Phase 2 Upadacitinib JAK inhibitor HiSCR week 12: superior to placebo; 38% (versus 24%)
NCT04756336 [90] Phase 2 LTX-109 Antimicrobial Results not posted
NCT03713632, NCT03713619 [10–12] Phase 3 Secukinumab IL-17 inhibitor

SUNSHINE: HiSCR week 16: 45% (versus 34%)

SUNRISE: HiSCR week 16: 42–46% (versus 31%)

NCT04762277

[91]

 Phase 2 Spesolimab IL-36R inhibitor Results not posted
NCT04493502 [92] Phase 2 LY3041658 CXCR1/CXCR2 inhibitor [93] Results submitted, quality control review has not concluded
NCT04856930 [94] Phase 2 Imsidolimab IL-36 receptor inhibitor [95] Results not posted
NCT05040698 [43] Phase 2 Fostamatinib Syk inhibitor Results not posted
NCT05216224 [96] Phase 2 ATI-450 Small molecule MK2 inhibitor Results not posted

NCT04092452

[97]

 Phase 2 PF-06650833 IRAK4 inhibitor Results submitted, quality control review has not concluded

NCT04092452

[97]

 Phase 2 PF-06700841 TYK2/JAK1 inhibitor Results submitted, quality control review has not concluded

NCT04092452

[97]

 Phase 2 PF-06826647 TYK2 inhibitor Results submitted, quality control review has not concluded

NCT03972280

[98]

 Phase 1 CSL324 Recombinant anti-G-CSF receptor monoclonal antibody Results not posted
NCT05286567 [62] Phase 1 RGRN-305 HSP90 inhibitor Results not posted

NCT04772885

[99]

 Phase 1 KT-474 IRAK4 degrader Results not posted

IL Interleukin, JAK Janus Kinase, PDE4 Phosphodiesterase-4, C5a Complement 5a, HiSCR Hidradenitis Suppurativa Clinical Response, MK2 MAPK-activated protein kinase 2, IRAK4 Interleukin-1 receptor-associated kinase 4, TYK2 Tyrosine kinase 2, G-CSF Granulocyte-colony stimulating factor, Syk Spleen tyrosine kinase, CXCR Chemokine receptor, HSP90 Heat shock protein 90